GALACTOSE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 180.0 | -3.2 | 5 | 6 | 110.0 | 1 | 1.0 |
- CAS
- 59234
- UNII
- X2RN3Q8DNE
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 33 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02180698 | 2014-10-01 | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma | Phase 1 | Recruiting |
| NCT02071758 | 2014-04-01 | Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers | Phase 1 | Active, Not Recruiting |
| NCT02014727 | 2014-01-01 | Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults | Phase 1 | Active, Not Recruiting |
| NCT02035657 | 2014-01-01 | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | Phase 1 | Recruiting |
| NCT01966900 | 2013-10-01 | The Safety and Immunogenicity of a Potential HIV Vaccine | Phase 1 | Recruiting |
| NCT01927159 | 2013-09-01 | Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers | Phase 1 | Active, Not Recruiting |
| NCT01991561 | 2013-06-01 | Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine. | Phase 2 | Active, Not Recruiting |
| NCT01922284 | 2013-06-01 | Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses | Phase 1 | Recruiting |
| NCT01751048 | 2013-03-01 | LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine | Phase 1 | Active, Not Recruiting |
| NCT01657929 | 2012-09-01 | H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers | Phase 1 | Completed |
| NCT01882218 | 2012-09-01 | Direct Peritoneal Resuscitation Plus Conventional Resuscitation | Phase 4 | Recruiting |
| NCT01864876 | 2012-09-01 | The Effects of GLA (5 mcg) on Human Volunteers | Phase 1 | Completed |
| NCT01599897 | 2012-08-01 | Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers | Phase 1 | Completed |
| NCT01385189 | 2012-05-01 | Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant | Phase 1 | Active, Not Recruiting |
| NCT01540474 | 2012-02-01 | Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults | Phase 1 | Completed |
| NCT01484548 | 2012-01-01 | Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers | Phase 1 | Completed |
| NCT01771055 | 2012-01-01 | Direct Peritoneal Resuscitation Effects in the Damage Control Patient | Phase 4 | Recruiting |
| NCT01397604 | 2011-07-01 | The Effects of GLA on Human Volunteers | Phase 1 | Completed |
| NCT01154049 | 2011-03-01 | Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis | Phase 1 | Active, Not Recruiting |
| NCT01201577 | 2009-10-01 | Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals | Phase 1 | Completed |
| NCT00816478 | 2008-12-01 | Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor | Phase 1 | Terminated |
| NCT00814255 | 2008-12-01 | Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial | Phase 2 | Completed |
| NCT00816504 | 2008-12-01 | Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 | Phase 1 | Suspended |
| NCT00668382 | 2007-07-01 | Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection | Phase 1 | Completed |
| NCT00668512 | 2007-03-01 | Intratumoral Injection Of Alpha-Gal Glycosphingolipids | Phase 1 | Completed |
| NCT01087710 | 2004-07-01 | Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children | Phase 2 | Completed |